{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:53:16Z","timestamp":1784775196120,"version":"3.55.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004035","name":"Jordan University of Science and Technology","doi-asserted-by":"publisher","award":["265\/2016"],"award-info":[{"award-number":["265\/2016"]}],"id":[{"id":"10.13039\/501100004035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Concerns have been raised about the influence of adverse drug effects on patient\u2019s health-related quality of life (HRQoL) in COPD patients. This study aimed to evaluate the impact of COPD treatment-related adverse effects on HRQoL in COPD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a cross-sectional study, COPD patients aged 40 years or older were identified and interviewed during their hospital visits. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) questionnaire was used for evaluating HRQoL. Potential treatment adverse effects were evaluated as experienced by participants during the last 2 weeks preceding the interview. The intensity of adverse effects was reported in the following categories: never, mild, moderate and severe. Multivariable linear regression model was performed to evaluate the influence of adverse drug effects on utility scores as an indicator of HRQoL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key findings<\/jats:title><jats:p>A total of 203 patients diagnosed with COPD were recruited in the current study. The mean utility score of the study sample was 0.68 (SD = 0.36). Moderate-severe constipation, moderate-severe confusion, mild urinary hesitation, moderate-severe urinary hesitation, moderate-severe dry eyes and moderate-severe drowsiness were significant predictors\/determinants for the average utility scores (coefficients were \u22120.099, \u22120.191, \u22120.111, \u22120.157 and \u22120.144, respectively). In addition, having higher COPD Assessment Test scores and severe disease was negatively associated with average utility scores (coefficients were \u22120.287 and \u22120.124, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Higher intensity of COPD treatment-related adverse effects has a negative influence on HRQoL in COPD patients. Anticholinergic drug effects are of concern in COPD adults\u2019 population.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ijpp\/riac052","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T15:37:56Z","timestamp":1658158676000},"page":"457-465","source":"Crossref","is-referenced-by-count":8,"title":["The influence of adverse drug effects on health-related quality of life in chronic obstructive pulmonary disease patients"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8345-4048","authenticated-orcid":false,"given":"Shoroq M","family":"Altawalbeh","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Jordan University of Science and Technology , Irbid , Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basima A","family":"Almomani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Jordan University of Science and Technology , Irbid , Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-5026","authenticated-orcid":false,"given":"Qais","family":"Alefan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Jordan University of Science and Technology , Irbid , Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleiman","family":"Mohammad Momany","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, Jordan University of Science and Technology , Irbid , Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qusai Y","family":"Al-Share","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Jordan University of Science and Technology , Irbid , Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"2022110504180291300_CIT0001","author":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease.","year":"2021"},{"key":"2022110504180291300_CIT0002","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1183\/09031936.06.00025805","article-title":"Chronic obstructive pulmonary disease: current burden and future projections","volume":"27","author":"Lopez","year":"2006","journal-title":"Eur Respir J"},{"key":"2022110504180291300_CIT0003","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(07)61380-4","article-title":"Global burden of COPD: risk factors, prevalence, and future trends","volume":"370","author":"Mannino","year":"2007","journal-title":"Lancet"},{"key":"2022110504180291300_CIT0004","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers","year":"2006","journal-title":"PLoS Med"},{"key":"2022110504180291300_CIT0005","first-page":"753","article-title":"Prevalence of chronic obstructive pulmonary disease among adult male cigarettes smokers: a community-based study in Jordan","volume":"9","author":"Al Omari","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2022110504180291300_CIT0006","first-page":"1229","article-title":"Deaths from chronic obstructive pulmonary disease\u2014United States, 2000-2005","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022110504180291300_CIT0007","doi-asserted-by":"crossref","first-page":"121S","DOI":"10.1378\/chest.121.5_suppl.121S","article-title":"COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity","volume":"121","author":"Mannino","year":"2002","journal-title":"Chest"},{"key":"2022110504180291300_CIT0008","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1053\/rmed.2003.1488","article-title":"Chronic obstructive pulmonary disease (COPD) in elderly subjects: impact on functional status and quality of life.","volume":"97","author":"Peruzza","year":"2003","journal-title":"Respir Med"},{"key":"2022110504180291300_CIT0009","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.rmed.2012.10.002","article-title":"Impact of comorbidities on COPD-specific health-related quality of life.","volume":"107","author":"Burgel","year":"2013","journal-title":"Respir Med"},{"key":"2022110504180291300_CIT0010","doi-asserted-by":"crossref","first-page":"e0132670","DOI":"10.1371\/journal.pone.0132670","article-title":"Comorbid influences on generic health-related quality of life in COPD: a systematic review.","volume":"10","author":"Huber","year":"2015","journal-title":"PLoS One"},{"key":"2022110504180291300_CIT0011","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-2466-14-102","article-title":"Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD","volume":"14","author":"Koskela","year":"2014","journal-title":"BMC Pulm Med"},{"key":"2022110504180291300_CIT0012","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ageing\/afj002","article-title":"Co-morbidity in older patients with COPD\u2014its impact on health service utilisation and quality of life, a community study","volume":"35","author":"Yeo","year":"2006","journal-title":"Age Ageing"},{"key":"2022110504180291300_CIT0013","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/00002512-200825050-00005","article-title":"Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing.","volume":"25","author":"Gupta","year":"2008","journal-title":"Drugs Aging"},{"key":"2022110504180291300_CIT0014","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1176\/appi.psy.41.6.465","article-title":"Functional impairment in COPD patients: the impact of anxiety and depression","volume":"41","author":"Kim","year":"2000","journal-title":"Psychosomatics"},{"key":"2022110504180291300_CIT0015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1157\/13079073","article-title":"Quality of life in patients with COPD: quantification criteria and therapeutic repercussions","volume":"205","author":"Miravitlles","year":"2005","journal-title":"Rev Clin Esp"},{"key":"2022110504180291300_CIT0016","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"key":"2022110504180291300_CIT0017","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/thoraxjnl-2011-201275","article-title":"Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications","volume":"68","author":"Singh","year":"2013","journal-title":"Thorax"},{"key":"2022110504180291300_CIT0018","doi-asserted-by":"crossref","first-page":"d3215","DOI":"10.1136\/bmj.d3215","article-title":"Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials.","volume":"342","author":"Singh","year":"2011","journal-title":"BMJ"},{"key":"2022110504180291300_CIT0019","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.300.12.1439","article-title":"Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.","volume":"300","author":"Singh","year":"2008","journal-title":"JAMA"},{"key":"2022110504180291300_CIT0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.amjopharm.2006.03.008","article-title":"Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events","volume":"4","author":"Ness","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"key":"2022110504180291300_CIT0021","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2165\/00002018-200124140-00005","article-title":"Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing.","volume":"24","author":"Newnham","year":"2001","journal-title":"Drug Saf"},{"key":"2022110504180291300_CIT0022","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/COPD.S1353","article-title":"Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety","volume":"3","author":"Rossi","year":"2008","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2022110504180291300_CIT0023","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1183\/09031936.00102509","article-title":"Development and first validation of the COPD assessment test.","volume":"34","author":"Jones","year":"2009","journal-title":"Eur Respir J"},{"key":"2022110504180291300_CIT0024","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000336549","article-title":"Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients","volume":"84","author":"Kelly","year":"2012","journal-title":"Respiration"},{"key":"2022110504180291300_CIT0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol G","year":"1990","journal-title":"Health Policy"},{"key":"2022110504180291300_CIT0026","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4103\/0256-4947.55313","article-title":"The validity and reliability of the Arabic version of the EQ-5D: a study from Jordan","volume":"29","author":"Aburuz","year":"2009","journal-title":"Ann Saudi Med"},{"key":"2022110504180291300_CIT0027","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/thoraxjnl-2015-207782","article-title":"The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference","volume":"71","author":"Nolan","year":"2016","journal-title":"Thorax"},{"key":"2022110504180291300_CIT0028","author":"EuroQol Group.","year":"2016"},{"key":"2022110504180291300_CIT0029","first-page":"61","article-title":"Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs)","volume":"6","author":"Weldring","year":"2013","journal-title":"Health Serv Insights"},{"key":"2022110504180291300_CIT0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/02770903.2019.1568454","article-title":"Respiratory tract infection-induced asthma exacerbations in adults with asthma: assessing predictors and outcomes.","volume":"57","author":"Altawalbeh","year":"2020","journal-title":"J Asthma"},{"key":"2022110504180291300_CIT0031","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1378\/chest.130.4.1117","article-title":"Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?","volume":"130","author":"Rutten-van M\u00f6lken","year":"2006","journal-title":"Chest"},{"key":"2022110504180291300_CIT0032","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1477-7525-9-26","article-title":"Comparison of health-related quality of life measures in chronic obstructive pulmonary disease","volume":"9","author":"Pickard","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"2022110504180291300_CIT0033","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1477-7525-4-31","article-title":"Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study","volume":"4","author":"Carrasco Garrido","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"2022110504180291300_CIT0034","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1183\/09031936.03.00101203","article-title":"Do GOLD stages of COPD severity really correspond to differences in health status?","volume":"22","author":"Antonelli-Incalzi","year":"2003","journal-title":"Eur Respir J"},{"key":"2022110504180291300_CIT0035","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1007\/s11136-015-0979-6","article-title":"Factors associated with the quality of life of Korean COPD patients as measured by the EQ-5D","volume":"24","author":"Hong","year":"2015","journal-title":"Qual Life Res"},{"key":"2022110504180291300_CIT0036","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/0970-2113.177438","article-title":"Health-related quality of life of chronic obstructive pulmonary disease patients: results from a community based cross-sectional study in Aligarh, Uttar Pradesh, India.","volume":"33","author":"Ahmed","year":"2016","journal-title":"Lung India"},{"key":"2022110504180291300_CIT0037","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejcdt.2012.08.012","article-title":"Quality of life in COPD patients.","volume":"61","author":"Zamzam","year":"2012","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"2022110504180291300_CIT0038","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3760\/cma.j.issn.0366-6999.20131359","article-title":"Determinants of health-related quality of life worsening in patients with chronic obstructive pulmonary disease at one year","volume":"127","author":"Liang","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"2022110504180291300_CIT0039","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.2147\/COPD.S252033","article-title":"Quality of life and limitations in daily life of stable COPD outpatients in a real-world setting in Austria \u2013 results from the CLARA project.","volume":"15","author":"Horner","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2022110504180291300_CIT0040","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12931-016-0356-1","article-title":"The association of lung function and St. George\u2019s respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis","volume":"17","author":"Martin","year":"2016","journal-title":"Respir Res"},{"key":"2022110504180291300_CIT0041","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12890-016-0238-9","article-title":"Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities","volume":"16","author":"Wacker","year":"2016","journal-title":"BMC Pulm Med"},{"key":"2022110504180291300_CIT0042","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12931-016-0401-0","article-title":"Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies","volume":"17","author":"Wacker","year":"2016","journal-title":"Respir Res"},{"key":"2022110504180291300_CIT0043","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2288-14-78","article-title":"Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form","volume":"14","author":"Lin","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2022110504180291300_CIT0044","doi-asserted-by":"crossref","first-page":"2050312117690404","DOI":"10.1177\/2050312117690404","article-title":"Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy","volume":"5","author":"Petrova","year":"2017","journal-title":"SAGE Open Med"},{"key":"2022110504180291300_CIT0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1753465808089455","article-title":"Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance","volume":"2","author":"Donohue","year":"2008","journal-title":"Ther Adv Respir Dis"},{"key":"2022110504180291300_CIT0046","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.rmed.2016.02.002","article-title":"Adverse events among COPD patients treated with long-acting anticholinergics and beta2-agonists in an outpatient respiratory clinic","volume":"113","author":"Rodrigue","year":"2016","journal-title":"Respir Med"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/30\/5\/457\/46811546\/riac052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/30\/5\/457\/46811546\/riac052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T09:36:53Z","timestamp":1727602613000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/article\/30\/5\/457\/6645734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,7,18]]},"published-print":{"date-parts":[[2022,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riac052","relation":{},"ISSN":["0961-7671","2042-7174"],"issn-type":[{"value":"0961-7671","type":"print"},{"value":"2042-7174","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,7,18]]}}}